Third-party reimbursement issues during a phase 1 trial of interleukin-2

Journal of the National Cancer Institute

Volumn 81, Issue 7, 1989, Pages 544-545

  Vogelzang, Nicholas J ^a   Richards, Jon M ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

DRUG SCREENING; ECONOMICS; HUMAN; LETTER; REIMBURSEMENT; UNITED STATES;

DRUG EVALUATION; HUMAN; INSURANCE, HEALTH, REIMBURSEMENT; INTERLEUKIN-2; UNITED STATES;

EID: 0024961799     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/81.7.544     Document Type: Letter

References (5)

1. Richards JM, Barker E, Latta J, et al Phase I study of weekly 24-hour infusions of recombinant human interieukin-2. J Nail Cancer Inst 80:1325-1328, 1988
2. Wittes RE: Paying for patient care in treatment research—who is responsible? Cancer Treat Rep 71:107-113, 1987
3. Moertel CG: On lymphokines, cytokines, and breakthroughs. JAMA 256:3141, 1986
4. Gilewski T, Vogelzang NJ: Cost-effectiveness and reimbursement issues in renal cell carcinoma. Semin Oncol 1989. In press
5. Fisher RI, Coltman CA, Doroshow JH, et al: Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 108:518-523, 1988